Skip to main content

Advertisement

Log in

Antisense MMP-9 RNA inhibits malignant glioma cell growth in vitro and in vivo

Neuroscience Bulletin Aims and scope Submit manuscript

Abstract

The matrix-degrading metalloproteinases (MMPs), particularly MMP-9, play important roles in the pathogenesis and development of malignant gliomas. In the present study, the oncogenic role of MMP-9 in malignant glioma cells was investigated via antisense RNA blockade in vitro and in vivo. TJ905 malignant glioma cells were transfected with pcDNA3.0 vector expressing antisense MMP-9 RNA (pcDNA-ASMMP9), which significantly decreased MMP-9 expression, and cell proliferation was assessed. For in vivo studies, U251 cells, a human malignant glioma cell line, were implanted subcutaneously into 4- to 6-week-old BALB/c nude mice. The mice bearing well-established U251 gliomas were treated with intratumoral pcDNA-AS-MMP9-Lipofectamine complex (AS-MMP-9-treated group), subcutaneous injection of endostatin (endostatin-treated group), or both (combined therapy group). Mice treated with pcDNA (empty vector)-Lipofectamine served as the control group. Four or eight weeks later, the volume and weight of tumor, MMP-9 expression, microvessel density and proliferative activity were assayed. We demonstrate that pcDNA-AS-MMP9 significantly decreased MMP-9 expression and inhibited glioma cell proliferation. Volume and weight of tumor, MMP-9 expression, microvessel density and proliferative activity in the antisense-MMP-9-treated and therapeutic alliance groups were significantly lower than those in the control group. The results suggest that MMP-9 not only promotes malignant glioma cell invasiveness, but also affects tumor cell proliferation. Blocking the expression of MMP-9 with antisense RNA substantially suppresses the malignant phenotype of glioma cells, and thus can be used as an effective therapeutic strategy for malignant gliomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Kachra Z, Beaulieu E, Delbecchi L, Mousseau N, Berthelet F, Moumdjian R, et al. Expression of matrix metalloproteinases and their inhibitors in human brain tumors. Clin Exp Metastasis 1999, 17: 555–566.

    Article  PubMed  CAS  Google Scholar 

  2. Kondraganti S, Mohanam S, Chintala SK, Kin Y, Jasti SL, Nirmala C, et al. Selective suppression of matrix metalloproteinase-9 in human glioblastoma cells by antisense gene transfer impairs glioblastoma cell invasion. Cancer Res 2000, 60: 6851–6855.

    PubMed  CAS  Google Scholar 

  3. Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A 2000, 97: 2202–2207.

    Article  PubMed  CAS  Google Scholar 

  4. VanMeter TE, Rooprai HK, Kibble MM, Fillmore HL, Broaddus WC, Pilkington GJ. The role of matrix metalloproteinase genes in glioma invasion: co-dependent and interactive proteolysis. J Neurooncol 2001, 53: 213–235.

    Article  PubMed  CAS  Google Scholar 

  5. Vihinen P, Ala-aho R, Kähäri VM. Matrix metalloproteinases as therapeutic targets in cancer. Curr Cancer Drug Targets 2005, 5: 203–220.

    Article  PubMed  CAS  Google Scholar 

  6. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13: 781–792.

    PubMed  CAS  Google Scholar 

  7. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 2003, 200: 448–464.

    Article  PubMed  CAS  Google Scholar 

  8. Vince GH, Wagner S, Pietsch T, Klein R, Goldbrunner RH, Roosen K, et al. Heterogeneous regional expression patterns of matrix metalloproteinases in human malignant gliomas. Int J Dev Neurosci 1999, 17: 437–445.

    Article  PubMed  CAS  Google Scholar 

  9. Chakravarti A, Palanichamy K. Overcoming therapeutic resistance in malignant gliomas: current practices and future directions. Cancer Treat Res 2008, 139: 173–189.

    PubMed  CAS  Google Scholar 

  10. Freije JM, Balbin M, Pendas AM, Sanchez LM, Puente XS, Lopez-Otin C. Matrix metalloproteinases and tumor progression. Adv Exp Med Biol 2003, 532: 91–107.

    Article  PubMed  CAS  Google Scholar 

  11. Gondi CS, Dinh DH, Gujrati M, Rao JS. Simultaneous downregulation of uPAR and MMP-9 induces overexpression of the FADD-associated protein RIP and activates caspase 9-mediated apoptosis in gliomas. Int J Oncol 2008, 33: 783–790.

    PubMed  CAS  Google Scholar 

  12. Iniesta P, Moran A, De Juan C, Gomez A, Hernando F, Garcia-Aranda C, et al. Biological and clinical significance of MMP-2, MMP-9, TIMP-1 and TIMP-2 in non-small cell lung cancer. Oncol Rep 2007, 17: 217–223.

    PubMed  CAS  Google Scholar 

  13. Koutroulis I, Zarros A, Theocharis S. The role of matrix metalloproteinases in the pathophysiology and progression of human nervous system malignancies: a chance for the development of targeted therapeutic approaches? Expert Opin Ther Targets 2008, 12: 1577–1586.

    Article  PubMed  CAS  Google Scholar 

  14. Chang C, Werb Z. The many faces of metalloproteases: cell growth, invasion, angiogenesis and metastasis. Trends Cell Biol 2001, 11: S37–S43.

    PubMed  CAS  Google Scholar 

  15. Iurlaro M, Loverro G, Vacca A, Cormio G, Ribatti D, Minischetti M, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest 1999, 29: 793–801.

    Article  PubMed  CAS  Google Scholar 

  16. Pellikainen JM, Ropponen KM, Kataja VV, Kellokoski JK, Eskelinen MJ, Kosma VM. Expression of matrix metalloproteinase (MMP)-2 and MMP-9 in breast cancer with a special reference to activator protein-2, HER2, and prognosis. Clin Cancer Res 2004, 10: 7621–7628.

    Article  PubMed  CAS  Google Scholar 

  17. Vihinen P, Kahari VM. Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99: 157–166.

    Article  PubMed  CAS  Google Scholar 

  18. Baker AH, Edwards DR, Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 2002, 115: 3719–3727.

    Article  PubMed  CAS  Google Scholar 

  19. Ozen O, Krebs B, Hemmerlein B, Pekrun A, Kretzschmar H, Herms J. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance. Clin Cancer Res 2004, 10: 4746–4753.

    Article  PubMed  Google Scholar 

  20. Kousidou OC, Roussidis AE, Theocharis AD, Karamanos NK. Expression of MMPs and TIMPs genes in human breast cancer epithelial cells depends on cell culture conditions and is associated with their invasive potential. Anticancer Res 2004, 24: 4025–4030.

    PubMed  CAS  Google Scholar 

  21. Yan L, Lin B, Gao L, Gao S, Liu C, Wang C, et al. Lewis (y) antigen overexpression increases the expression of MMP-2 and MMP-9 and invasion of human ovarian cancer cells. Int J Mol Sci 2010, 11: 4441–4452.

    Article  PubMed  CAS  Google Scholar 

  22. Yager D, Sharma SC. Evidence for visual function mediated by anomalous projection in goldfish. Nature 1975, 256: 490–491.

    Article  PubMed  CAS  Google Scholar 

  23. Munaut C, Noel A, Hougrand O, Foidart JM, Boniver J, Deprez M. Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas. Int J Cancer 2003, 106: 848–855.

    Article  PubMed  CAS  Google Scholar 

  24. Roderfeld M, Rath T, Lammert F, Dierkes C, Graf J, Roeb E. Innovative immunohistochemistry identifies MMP-9 expressing macrophages at the invasive front of murine HCC. World J Hepatol 2010, 2: 175–179.

    PubMed  Google Scholar 

  25. Wang HH, Hsieh HL, Yang CM. Calmodulin kinase II-dependent transactivation of PDGF receptors mediates astrocytic MMP-9 expression and cell motility induced by lipoteichoic acid. J Neuroinflammation 2010, 7: 84. doi: 10.1186/1742-2094-7-84

    Article  PubMed  CAS  Google Scholar 

  26. Hsieh HL, Wang HH, Wu WB, Chu PJ, Yang CM. Transforming growth factor-beta1 induces matrix metalloproteinase-9 and cell migration in astrocytes: roles of ROS-dependent ERK- and JNK-NF-kappaB pathways. J Neuroinflammation 2010, 7: 88. doi: 10.1186/1742-2094-7-88.

    Article  PubMed  CAS  Google Scholar 

  27. Raghu H, Sodadasu PK, Malla RR, Gondi CS, Estes N, Rao JS. Localization of uPAR and MMP-9 in lipid rafts is critical for migration, invasion and angiogenesis in human breast cancer cells. BMC Cancer 2010, 10: 647. doi: 10.1186/1471-2407-10-647.

    Article  PubMed  CAS  Google Scholar 

  28. Veeravalli KK, Chetty C, Ponnala S, Gondi CS, Lakka SS, Fassett D, et al. MMP-9, uPAR and cathepsin B silencing downregulate integrins in human glioma xenograft cells in vitro and in vivo in nude mice. PLoS One 2010, 5: e11583.

    Article  PubMed  Google Scholar 

  29. Nyberg P, Heikkila P, Sorsa T, Luostarinen J, Heljasvaara R, Stenman UH, et al. Endostatin inhibits human tongue carcinoma cell invasion and intravasation and blocks the activation of matrix metalloprotease-2, -9, and -13. J Biol Chem 2003, 278: 22404–22411.

    Article  PubMed  CAS  Google Scholar 

  30. Rogatsch H, Hittmair A, Reissigl A, Mikuz G, Feichtinger H. Microvessel density in core biopsies of prostatic adenocarcinoma: a stage predictor? J Pathol 1997, 182: 205–210.

    Article  PubMed  CAS  Google Scholar 

  31. Lakka SS, Rajan M, Gondi C, Yanamandra N, Chandrasekar N, Jasti SL, et al. Adenovirus-mediated expression of antisense MMP-9 in glioma cells inhibits tumor growth and invasion. Oncogene 2002, 21: 8011–8019.

    Article  PubMed  CAS  Google Scholar 

  32. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88: 277–285.

    Article  PubMed  Google Scholar 

  33. Guan KP, Ye HY, Yan Z, Wang Y, Hou SK. Serum levels of endostatin and matrix metalloproteinase-9 associated with high stage and grade primary transitional cell carcinoma of the bladder. Urology 2003, 61: 719–723.

    Article  PubMed  Google Scholar 

  34. Singh RS, Goncalves C, Sandrin P, Pichon C, Midoux P, Chaudhuri A. On the gene delivery efficacies of pH-sensitive cationic lipids via endosomal protonation: a chemical biology investigation. Chem Biol 2004, 11: 713–723.

    Article  PubMed  CAS  Google Scholar 

  35. Basile DP, Fredrich K, Weihrauch D, Hattan N, Chilian WM. Angiostatin and matrix metalloprotease expression following ischemic acute renal failure. Am J Physiol Renal Physiol 2004, 286: F893–902.

    Article  PubMed  CAS  Google Scholar 

  36. Talvensaari-Mattila A, Paakko P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer 2003, 89: 1270–1275.

    Article  PubMed  CAS  Google Scholar 

  37. Mroczko B, Groblewska M, Okulczyk B, Kedra B, Szmitkowski M. The diagnostic value of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of matrix metalloproteinases 1 (TIMP-1) determination in the sera of colorectal adenoma and cancer patients. Int J Colorectal Dis 2010, 25: 1177–1184.

    Article  PubMed  Google Scholar 

  38. Wroblewski LE, Pritchard DM, Carter S, Varro A. Gastrinstimulated gastric epithelial cell invasion: the role and mechanism of increased matrix metalloproteinase 9 expression. Biochem J 2002, 365: 873–879.

    PubMed  CAS  Google Scholar 

  39. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004, 10: 3110–3116.

    Article  PubMed  CAS  Google Scholar 

  40. Belkin AM, Akimov SS, Zaritskaya LS, Ratnikov BI, Deryugina EI, Strongin AY. Matrix-dependent proteolysis of surface transglutaminase by membrane-type metalloproteinase regulates cancer cell adhesion and locomotion. J Biol Chem 2001, 276: 18415–18422.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Shizhu Yu or Junwei Hao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sun, C., Wang, Q., Zhou, H. et al. Antisense MMP-9 RNA inhibits malignant glioma cell growth in vitro and in vivo . Neurosci. Bull. 29, 83–93 (2013). https://doi.org/10.1007/s12264-012-1296-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12264-012-1296-5

Keywords

Navigation